- The FDA has approved BeiGene Ltd BGNE Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenström's macroglobulinemia (WM).
- Brukinsa WM approval is the second therapy approved specifically for the treatment of this rare type of lymphoma.
- The approval is primarily based on results from Phase 3 ASPEN trial.
- The very good partial response (VGPR) rate was 28% with Brukinsa, compared to 19% with ibrutinib.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: BGNE stock is up 0.35% at $328.39 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
